Antiviral treatment may lead to drug-resistant H1N1 virus: NIAID Two people with compromised immune systems who became ill with 2009 H1N1 influenza developed drug-resistant strains of virus after significantly less than two weeks on therapy, statement doctors from the National Institute of Allergy and Infectious Diseases , area of the National Institutes of Health. Doctors who deal with prolonged influenza infection must be aware that even a short span of antiviral treatment may lead to drug-resistant virus, say the authors, and clinicians should consider this possibility as they develop initial treatment approaches for their patients who have impaired immune function. Both individuals in the new report developed level of resistance to the main element influenza drug oseltamivir , and one also demonstrated clinical resistance to some other antiviral agent, in experimental testing now, intravenous peramivir, note senior authors Matthew J read .
They are glycoproteins macromolecules with a central protein chain and long part chains manufactured from polysaccharides. The altered MUC1 will be a good target molecule for antibodies in immunological antitumor therapy. The issue with this approach is certainly that such sugar-containing compounds are completely ineffective at stimulating the immune system to create antibodies. Immunization is only effective if the vaccine can be anchored to an immunizing carrier proteins by means of a spacer, explains Kunz. This would be extremely easy to perform with polysaccharides, but turns out to be very complicated with glycoproteins, because the protein portion of the molecule offers many reactive organizations that are attacked in the coupling response.